Entrusted financial announcement
Release time:
2021-05-20
证券简称:尖峰集团 证券代码:600668 编号:临2019-036
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
委托理财公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
- 委托理财受托方:渤海银行股份有限公司金华分行
- 委托理财金额:5000万元人民币
- 委托理财产品名称:渤海银行[S191620]号结构性存款产品
- 委托理财投资类型:保本浮动收益型结构性存款
- 委托理财期限:2019年11月15日—2020年2月14日
- 履行的审议程序:2019年4月26日,公司召开的第十届董事会第10次会议审议通过了《关于授权公司董事长利用自有资金进行委托理财的议案》。授权公司董事长行使不超过人民币5亿元的委托理财的决策权,在该额度内资金可以滚动使用,但任一时点存续的委托理财余额合计不得超过5亿元,每笔委托理财的期限均不得超过12个月。详见本公司在2019年4月30日在上海证券交易所网站等披露的《关于授权公司董事长利用自有资金进行委托理财的公告》(临2019-012)。
一、本次委托理财概况
(一)委托理财目的
公司在不影响主营业务的正常开展、日常运营资金周转需要和资金安全的前提下,使用暂时闲置自有资金5000万元购买渤海银行金华分行发售的单位结构性存款[S191620]号产品。本产品为保本浮动收益型产品,安全性高、流动性好、风险性低。公司通过进行适度的低风险理财产品投资业务,有利于提高资金使用效率,且获得一定的理财收益。
(二)资金来源
本次委托理财的资金来源系公司自有资金。
(三)委托理财产品的基本情况
|
受托方 名称 |
产品 类型 |
产品 名称 |
金额 (万元) |
预计年化 收益率 |
预计收益金额 (万元) |
|
渤海银行股份有限公司金华分行 |
银行结构性存款产品 |
渤海银行[S191620]号结构性存款产品 |
5000 |
0.3%—4.05% |
3.7-50.5 |
|
产品 期限 |
收益 类型 |
结构化 安排 |
参考年化 收益率 |
预计收益 (万元) |
是否构成 关联交易 |
|
91天 |
保本浮动收益型 |
无 |
0.3%—4.05% |
3.7-50.5 |
否 |
(四)公司对委托理财相关风险的内部控制
1、委托理财情况由公司审计部门进行日常监督,定期对公司委托理财的进展情况、盈亏情况、风险控制情况和资金使用情况进行审计、核实。
2、公司进行委托理财,应当选择资信、财务状况良好、盈利能力强的合格专业理财机构作为受托方,并与受托方签订书面合同,明确委托理财的金额、期间、投资品种、双方的权利义务及法律责任等,必要时要求提供担保。公司董事会指派公司财务负责人跟踪委托理财的进展情况及投资安全状况。财务负责人发现公司委托理财出现异常情况时应当及时向董事会报告,以便董事会立即采取有效措施回收资金,避免或减少公司损失。
3、公司独立董事可以对委托理财情况进行检查。独立董事在公司内部审计核查的基础上,以董事会审计委员会核查为主,必要时由二名以上独立董事提议,有权聘任独立的外部审计机构进行委托理财的专项审计。独立董事应对提交董事会审议的委托理财事项发表独立意见。
4、公司监事会有权对公司委托理财情况进行定期或不定期的检查。如发现违规操作情况可提议召开董事会审议停止公司的相关投资活动。
5、公司委托理财具体执行人员及其他知情人员在相关信息公开披露前不得将公司投资情况透露给其他个人或组织,但法律、法规或规范性文件另有规定的除外。
6、凡违反相关法律法规、本制度及公司其他规定或由于工作不尽职,致使公司遭受损失或收益低于预期,将视具体情况,追究相关人员的责任。
本次公司购买渤海银行发行的保本浮动收益型结构性存款,在前述董事会对董事长的授权范围内,该产品风险程度低,符合公司内部资金管理要求。
二、本次委托理财的具体情况
(一)委托理财合同主要条款
客户:浙江尖峰集团股份有限公司
银行:渤海银行股份有限公司金华分行
|
产品名称 |
渤海银行[S191620]号结构性存款产品 |
|
产品代码 |
[S191620] |
|
产品类型 |
保本浮动收益型 |
|
交易账户 |
户名:浙江尖峰集团股份有限公司 账号:2000150253000218 |
|
结构性存款本金 |
(大写)伍仟万元,(小写)50,000,000.00元 |
|
本金保证 |
银行承诺保障结构性存款本金 |
|
存款期限 |
91天 |
|
存款成立日 |
2019年11月15日 |
|
存款到期日 |
2020年2月14日 |
|
交易范围 |
本产品为结构性存款产品,其衍生产品部分与3个月期美元计伦敦同业拆借利率(Libor)挂钩 |
|
挂钩标的 |
3个月期美元计伦敦同业拆借利率(3-month USD Libor) |
|
期末定价日
|
(2)在本产品提前终止情形下,为提前终止日前两个工作日(遇节假日,标的价格以上一个市场交易日价格为准;遇市场中断日,标的价格由银行决定) |
|
期末价格 |
挂钩标的在期末定价日的路透系统LIBOR01页面中,3-month USD Libor在伦敦时间上午11点的价格 |
|
存款收益计算 |
(1)如果挂钩标的的期末价格小于或等于9.5%,则客户预期收益率为:【4.05】%(年);客户预期收益为:结构性存款本金×【4.05】%×实际产品天数/365; (2)如果挂钩标的的期末价格大于9.5%,则客户预期收益率为:【0.3】%(年),即当期人民币活期存款利率;客户预期收益为:结构性存款本金×当期人民币活期存款利率×实际产品天数/365。 |
|
币种 |
人民币 |
|
产品到期资金到账日 |
实际到期日后3个工作日内 |
|
费用 |
本产品银行不收取任何销售手续费、托管费等相关费用 特别约定:无 与费用价格有关的例外条款或限制性条款:无 |
|
提前终止权 |
客户无权提出提前终止(全部或者部分)本产品 如出现如下情况,银行有权但无义务提前终止本产品: (1)国家金融政策出现重大调整并影响到终止本产品的正常运作; (2)市场发生极端重大变动或突发性事件等情形; (3)本产品所交易的金融工具提前终止。 一旦银行提前终止本产品,将于确定的终止日前2个工作日通知客户,并在提前终止日后3个工作日内向客户返还本金及收益,收益按实际期限计算。 |
|
提前赎回权 |
客户无权提前赎回(全部或部分)本产品 |
|
本金及收益的派发 |
本产品实际到期后一次性支付本金及收益 |
|
争议处理 |
与《交易协议书》有关的一切争议,由银行所在地人民法院管辖 |
(二)委托理财的资金投向
本次公司委托理财的资金投向为渤海银行结构性存款产品。
(三)风险控制分析
公司本次使用自有资金购买渤海银行金华分行发售的保本浮动收益型结构性存款,在公司第十届董事会第10次会议授权董事长决策范围之内。公司财务部建立台账负责对短期理财产品进行管理,建立健全会计账目,做好资金使用的财务核算工作。公司在本次交易后将履行信息披露义务,并实时跟踪进展情况及时披露。
渤海银行结构性存款属于保本浮动收益型产品,渤海银行股份有限公司金华分行承诺保障结构性存款本金,因此该产品风险程度较低,符合公司《委托理财管理制度》的要求。
三、委托理财受托方的情况
(一)受托方的基本情况
|
名称 |
成立时间 |
法定代表人 |
注册 资本 (万元) |
主营业务 |
主要股东及实际控制人 |
是否为本次交易专设 |
|
渤海银行股份有限公司 |
2005-12-30 |
李伏安 |
1,445,000 |
吸收公众存款;发放短期、中期和长期贷款;办理国内外结算;办理票据承兑与贴现;发行金融证券;代理发行、代理兑付、承销政府债券;买卖政府债券、金融债券;从事同业拆借;买卖、代理买卖外汇;结汇、售汇业务;从事银行卡业务;提供信用证服务及担保;代理收付款项及保险兼业代理;提供保管箱服务;从事衍生产品交易业务;证券投资基金托管、保险资金托管业务;证券投资基金销售业务;经国务院银行业监督管理机构批准的其他业务。(依法须经批准的项目,经相关部门批准后方可开展经营活动) |
天津泰达投资控股有限公司 |
否 |
(二)受托方最近一年又一期主要财务指标
单位:万元
|
|
2018年12月31日 |
2019年9月30日 |
|
总资产 |
103,445,133 |
109,228,322 |
|
归属于股东的净资产 |
5,585,912 |
8,087,044 |
|
|
2018年度 |
2019年1-9月 |
|
营业收入 |
2,317,483 |
2,113,690 |
|
归属于股东的净利润 |
708,016 |
662,619 |
(三)渤海银行股份有限公司与本公司之间在产权、业务、资产、债权债务、人员等方面均不存在关联关系。
四、对公司的影响
(一)本公司最近一年又一期主要财务指标
单位:万元
|
项目 |
2018年12月31日 |
2019年9月30日 |
|
总资产 |
490,138.84 |
549,699.87 |
|
总负债 |
145,145.53 |
158,058.70 |
|
归属于公司股东的净资产 |
316,270.67 |
352,998.15 |
|
|
2018年度 |
2019年1-9月 |
|
经营性现金流量净额 |
65,254.42 |
35,864.95 |
|
营业收入 |
336,221.53 |
256,799.88 |
|
归属于公司股东的净利润 |
58,850.21 |
61,457.09 |
公司本次购买渤海银行结构性存款理财产品是在不影响主营业务的正常开展、日常运营资金周转需要和资金安全的前提下,使用闲置自有资金进行委托理财业务,有利于提高公司资金使用效率,获得一定的理财收益。
(二)截止2019年9月30日,公司货币资金为40,863.63万元,本次购买渤海银行结构性存款支付的金额占最近一期期末货币资金的12.24%,对本公司未来主营业务、财务状况、经营成果和现金流量等不会造成重大的影响。
(三)根据企业会计准则第22号—《金融工具确认和计量》规定,该结构性银行存款符合以摊余成本计量的金融资产,列示于资产负债表—交易性金融资产,利息收益计入利润表—投资收益。
五、风险提示
尽管本公司购买的结构性存款属于短期保本浮动收益型的低风险理财产品,但金融市场受宏观经济影响较大,不排除该项投资受到市场风险、信用风险、政策风险、流动性风险、不可抗力风险等风险从而影响收益。
六、独立董事意见
公司召开的第十届董事会第10次会议审议通过了《关于授权公司董事长决定委托理财的议案》,独立董事发表了独立意见,认为:该决议的形成符合《公司法》、公司《章程》等有关规定,没有损害中小股东的利益。
七、截至本公告日,公司最近十二个月使用自有资金或募集资金委托理财的情况 单位:万元
|
序号 |
理财产品类型 |
实际投入 金额 |
实际收回 本金 |
实际收益 |
尚未收回 本金金额 |
|
1 |
薪加薪16号人民币结构性存款产品 |
5,000.00 |
5,000.00 |
56.61 |
/ |
|
2 |
蕴通财富定期型结构性存款 |
5,000.00 |
5,000.00 |
17.53 |
/ |
|
3 |
渤海银行S181456号结构性存款产品 |
5,000.00 |
5,000.00 |
52.98 |
/ |
|
4 |
渤海银行S181718号结构性存款产品 |
3,000.00 |
3,000.00 |
9.86 |
/ |
|
5 |
薪加薪16号人民币结构性存款产品 |
4,000.00 |
4,000.00 |
13.33 |
/ |
|
6 |
蕴通财富定期型结构性存款 |
5,000.00 |
5,000.00 |
18.70 |
/ |
|
7 |
薪加薪16号人民币结构性存款产品 |
4,000.00 |
4,000.00 |
42.41 |
/ |
|
8 |
渤海银行S190019号结构性存款理财产品 |
4,000.00 |
4,000.00 |
41.88 |
/ |
|
9 |
与利率挂钩的结构性存款产品 |
4,000.00 |
4,000.00 |
41.92 |
/ |
|
10 |
薪加薪16号人民币结构性存款产品 |
5,000.00 |
5,000.00 |
51.16 |
/ |
|
11 |
蕴通财富定期型结构性存款 |
3,000.00 |
3,000.00 |
41.61 |
/ |
|
12 |
薪加薪16号人民币结构性存款产品 |
5,000.00 |
5,000.00 |
51.16 |
/ |
|
13 |
汇利丰2019年4505期对公定制人民币结构性存款产品 |
5,000.00 |
5,000.00 |
50.49 |
/ |
|
14 |
薪加薪16号人民币结构性存款产品 |
4,000.00 |
4,000.00 |
38.96 |
/ |
|
15 |
渤海银行S190534号结构性存款理财产品 |
4,000.00 |
4,000.00 |
38.89 |
/ |
|
16 |
与利率挂钩的结构性存款产品 |
4,000.00 |
4,000.00 |
38.39 |
/ |
|
17 |
薪加薪16号人民币结构性存款产品 |
5,000.00 |
5,000.00 |
53.51 |
/ |
|
18 |
薪加薪16号人民币结构性存款产品 |
10,000.00 |
10,000.00 |
216.58 |
/ |
|
19 |
汇利丰2019年5015期对公定制人民币结构性存款产品 |
10,000.00 |
10,000.00 |
104.71 |
/ |
|
20 |
薪加薪16号人民币结构性存款产品 |
8,000.00 |
8,000.00 |
136.32 |
/ |
|
21 |
薪加薪16号人民币结构性存款产品 |
8,000.00 |
8,000.00 |
115.51 |
/ |
|
22 |
薪加薪16号人民币结构性存款产品 |
5,000.00 |
5,000.00 |
48.70 |
/ |
|
23 |
慧盈人民币单位结构性存款产品 |
5,000.00 |
5,000.00 |
50.03 |
/ |
|
24 |
薪加薪16号人民币结构性存款产品 |
4,000.00 |
/ |
/ |
4,000.00 |
|
25 |
渤海银行S190019号结构性存款理财产品 |
10,000.00 |
/ |
/ |
10,000.00 |
|
26 |
薪加薪16号人民币结构性存款产品 |
10,000.00 |
/ |
/ |
10,000.00 |
|
27 |
渤海银行S191620号结构性存款理财产品 |
5,000.00 |
/ |
/ |
5,000.00 |
|
合计 |
149,000.00 |
120,000.00 |
1,331.24 |
29,000.00 |
|
|
最近12个月内单日最高投入金额 |
50,000.00 |
||||
|
最近12个月内单日最高投入金额/最近一年净资产(%) |
15.81 |
||||
|
最近12个月委托理财累计收益/最近一年净利润(%) |
2.26 |
||||
|
目前已使用的理财额度 |
29,000.00 |
||||
|
尚未使用的理财额度 |
21,000.00 |
||||
|
总理财额度 |
50,000.00 |
||||
特此公告
浙江尖峰集团股份有限公司
董事会
二〇一九年十一月十五日
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11